Objectives: The objective of this work was to evaluate the in vitro activity of amphotericin B, itraconazole, voriconazole, posaconazole, caspofungin and terbinafine against clinical isolates of Scytalidium dimidiatum and Scytalidium hyalinum.
Introduction
Scytalidium dimidiatum, a synanamorph of Natrassia mangiferae, and Scytalidium hyalinum are two non-dermatophyte moulds responsible for dermatomycosis with clinical manifestations similar to those caused by Trichophyton rubrum. They are rarely, and mainly in immunosuppressed patients, responsible for deep infections. Scytalidioses are endemic in tropical and subtropical areas and represent 35% to 45% of dermatomycosis of feet in these countries. 1 However, many cases are now reported from temperate countries among immigrants from these tropical areas. 2 At present, there is no orally or topically effective treatment for skin and nail infections due to Scytalidium, 1 and amphotericin B, used to treat deep infections, cannot be easily used in dermatology practice with only a lotion formulation. Recently, the new triazole agents voriconazole and posaconazole were shown to have clinical activity in phaeohyphomycete infections. 3, 4 It suggests that they could be active against S. dimidiatum, a black fungus, and S. hyalinum, which is considered as a closely related mutant of S. dimidiatum. 1 As no study has yet evaluated the in vitro susceptibility of Scytalidium, we chose to test antifungal drugs available in dermatology practice along with the newer drugs, voriconazole, posaconazole and caspofungin.
The objective of the present study was to describe the in vitro activities of voriconazole, posaconazole, caspofungin and terbinafine as compared with those of amphotericin B and itraconazole against 32 isolates of Scytalidium [17 S. dimidiatum (Sd) and 15 S. hyalinum (Sh)] from our institution.
Materials and methods
Isolates were recovered from toenail (10 S. dimidiatum, 6 S. hyalinum), fingernail (2 S. dimidiatum, 1 S. hyalinum) and sole or toeweb (5 S. dimidiatum, 8 S. hyalinum) cultures on Sabouraud agar slants supplemented with antibiotics (SA) (Bio-Rad, Marnes la Coquette, France). Species were identified according to usual macroscopic and microscopic examination criteria. Isolates were subcultured on SA agar slants at 278C for 14 days before testing. Caspofungin (Merck Research Laboratories, Rahway, NJ, USA), terbinafine (ChemoIberica, Madrid, Spain), voriconazole (Pfizer Pharmaceutical Group, New York, NY, USA), posaconazole (Schering-Plough, Kenilworth, NJ, USA), itraconazole and amphotericin B (Sigma, France) were dissolved in dimethyl sulphoxide (Sigma, France) and diluted in RPMI 1640 medium buffered with MOPS (Sigma, France), pH 7.0, to a final concentration range of 16-0.03 mg/L. Microdilution testing was performed using the CLSI M38-A microdilution method.
5 Inocula were prepared by scraping colonies with a loop in sterile 0.85% saline and vigorously vortexed. Fungal suspensions were settled for $5 min. The upper suspension was adjusted with a haemocytometer to a final concentration of 5 Â 10 3 -5 Â 10 4 cfu/mL. Inoculum concentration was retrospectively controlled by subculture on SA. A 0.1 mL fungal inoculum was added to each well, except negative controls and the 96-well round-bottomed microtitre plates were incubated at 358C. The MIC endpoints were read at 96 h and were defined as the lowest concentration to inhibit 100% of fungal growth compared with the growth control for amphotericin B and to inhibit 80% for azoles, terbinafine and caspofungin. MIC 50 and MIC 90 are reported as MICs at which at least 50% or 90% of isolates are inhibited. Quality control was ensured by testing the Candida krusei ATCC 6258 strain. The results of this study show that voriconazole exhibits the lowest MICs against Scytalidium compared with amphotericin B, the most active drug until now. The MICs of itraconazole and amphotericin B are consistent with other in vitro data reported by different investigators or case reports. 6 -8 Antifungal activities of posaconazole, caspofungin and terbinafine vary with isolates, some of them with low MIC values and others with high MIC values. Although the two species of Scytalidium are equally resistant to antifungals in clinical practice, in vitro, S. dimidiatum seems more resistant when compared with S. hyalinum. The capacity of S. dimidiatum to produce melanin-like pigments unlike S. hyalinum could explain this difference since melanization has been shown to play a role in resistance to antifungal drugs in other fungi. 9 The clinical relevance of these in vitro results may be subject to debate since interpretation of mould MICs is known to be problematic. In several case reports, a poor correlation was found between in vitro and in vivo results. A poor clinical response can be observed despite MIC values within the range of achievable levels at the site of infection, as for terbinafine, known to be ineffective for treating superficial scytalidiosis. However, treatment with intravenous amphotericin B has been beneficial in deep scytalidiosis, 6 -8 and topical amphotericin B has been used somewhat successfully to treat Scytalidium onychomycosis (C. Lacroix, G. Kac and M. Feuilhade de Chauvin, unpublished data). In two recent case reports with invasive S. dimidiatum infections, isolates were tested in vitro with voriconazole and showed MICs of 0.012 and 1 mg/L. 7, 10 Recently Dunn et al. 6 and Willinger et al. 10 reported two cases of invasive S. dimidiatum infection in immunocompromised patients treated with voriconazole with stabilization of the disease or eradication of the mould. These reports as well as our in vitro data suggest that voriconazole could be a therapeutic option or an alternative to amphotericin B in the treatment of deep Scytalidium infections. Furthermore, as voriconazole can be orally administrated unlike amphotericin B, it could be easily used to treat Scytalidium superficial infections. In conclusion, voriconazole represents a promising agent for the treatment of Scytalidium infections. The clinical value of these in vitro results should be determined by animal models and clinical trials.
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